Microbot Medical Inc. (MBOT)

NASDAQ: MBOT · IEX Real-Time Price · USD
1.020
-0.040 (-3.77%)
At close: May 24, 2024, 4:00 PM
1.040
+0.020 (1.96%)
Pre-market: May 28, 2024, 4:40 AM EDT
-3.77%
Market Cap 14.69M
Revenue (ttm) n/a
Net Income (ttm) -10.26M
Shares Out 14.40M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 49,614
Open 1.070
Previous Close 1.060
Day's Range 1.020 - 1.020
52-Week Range 0.860 - 3.660
Beta 1.70
Analysts Strong Buy
Price Target 7.00 (+586.28%)
Earnings Date May 15, 2024

About MBOT

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, a... [Read more]

Sector Healthcare
Founded 2010
Employees 21
Stock Exchange NASDAQ
Ticker Symbol MBOT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for MBOT stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(586.28% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular procedures The next step of the collab...

4 weeks ago - GlobeNewsWire

Microbot Medical Shares Status Following Recent Geopolitical Events

All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel

6 weeks ago - GlobeNewsWire

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this application The Investigational Device Exemption (IDE) application follows t...

4 months ago - GlobeNewsWire

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters

All of the cash payable to the plaintiffs in the settlement will be covered by Microbot's insurance carrier and will not impact company's cash position All of the cash payable to the plaintiffs in the...

4 months ago - GlobeNewsWire

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Following the recent positive results of its pivotal GLP pre-clinical study, the Company added a CRA to facilitate the company's first in human clinical study Following the recent positive results of ...

4 months ago - GlobeNewsWire

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

BRAINTREE, Mass., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the entry into a de...

5 months ago - GlobeNewsWire

Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met

The results of the study will support the Company's IDE submission to the FDA to commence its human clinical study The results of the study will support the Company's IDE submission to the FDA to comm...

5 months ago - GlobeNewsWire

Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic

The first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatments The first phase in the collaborat...

5 months ago - GlobeNewsWire

Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study

The final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company's IDE submission to the FDA to commence its human clinical stu...

6 months ago - GlobeNewsWire

Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities

The former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase. The former Senio...

6 months ago - GlobeNewsWire

Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process

The V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDA The V&V process is an additional key milestone toward regula...

7 months ago - GlobeNewsWire

Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office

BRAINTREE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today...

7 months ago - GlobeNewsWire

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study

Follow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse events Follow up visual exami...

7 months ago - GlobeNewsWire

Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024

The Company's designated N otified B ody confirmed dates for conducting audits for ISO 13485 certification to ensure Microbot complies with the QMS requirements of the EU MDR

7 months ago - GlobeNewsWire

Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

BRAINTREE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces that the United States District ...

7 months ago - GlobeNewsWire

Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System

BRAINTREE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces the successful initial outcomes ...

7 months ago - GlobeNewsWire

Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial

The engagement is an additional step in the Company's path towards marketing clearance with the FDA The engagement is an additional step in the Company's path towards marketing clearance with the FDA

8 months ago - GlobeNewsWire

Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023

The presentation follows successful extensive uses of the Company's endovascular robotic system in pre-clinical studies The presentation follows successful extensive uses of the Company's endovascular...

9 months ago - GlobeNewsWire

Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System

The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercializati...

10 months ago - GlobeNewsWire

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies Professor Francois H. Cornelis is a world renown neuro in...

10 months ago - GlobeNewsWire

Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in Europe

Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European Union Engagement includes audit plans for ISO 13485 certificat...

10 months ago - GlobeNewsWire

Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board

Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional Radiology Believes that the reduction in radiation exposure the LIBER...

11 months ago - GlobeNewsWire

Microbot Medical Raises a Total of $7.6 Million in Gross Proceeds from Four Recent Registered Direct Offerings

HINGHAM, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it closed its previously announced registered direct offering for the purchase and sale of 6...

11 months ago - GlobeNewsWire

Microbot Medical Expand IP protection in Japan

Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robotic Drive Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robo...

1 year ago - GlobeNewsWire

Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe

Company Believes the Continuous Accumulation of Peer-Reviewed Data will Accelerate the Adoption of its Novel Interventional Endovascular System Once Commercialized Company Believes the Continuous Accu...

1 year ago - GlobeNewsWire